Form 4: Zoetis EVP Esch Reports Routine Stock Transactions
Insider Transaction Report
Zoetis Inc. Executive Vice President Kevin Esch reported routine acquisitions of common stock from restricted stock unit vesting and subsequent tax-related dispositions.
Summary
- Kevin Esch, Executive Vice President of Zoetis Inc., reported transactions involving the company's common stock.
- On February 6, 2026, 43 shares of common stock were acquired upon the vesting and settlement of restricted stock units (RSUs).
- On the same date, 15 shares of common stock were disposed of at a price of $127.42 per share to cover tax withholding obligations.
- Following these transactions on February 6, 2026, direct beneficial ownership of common stock was 295 shares.
- On February 8, 2026, 50 shares of common stock were acquired upon the vesting and settlement of additional RSUs.
- Also on February 8, 2026, 18 shares of common stock were disposed of at a price of $127.42 per share for tax withholding.
- After these transactions on February 8, 2026, direct beneficial ownership of common stock was 327 shares.
- The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
- Indirect beneficial ownership includes 122.9323 common stock equivalents held in the Zoetis Inc. Savings Plan (401(k) plan) as of December 31, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation and tax-related transactions under a pre-established plan, with no significant positive or negative implications for the company's operational or financial performance.
Positives
- The vesting of restricted stock units indicates continued executive compensation and retention, aligning management interests with shareholder value.
- Transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned and routine activity rather than discretionary sales based on new information.
Negatives
- Disposal of shares for tax withholding, while routine, reduces the executive's direct equity stake in the company.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that these transactions are routine compensation events, typical for executives in publicly traded companies, reflecting the settlement of equity awards and subsequent tax obligations. Such filings are common across the pharmaceutical and animal health sectors.
Comparison to Industry Standards
- StockSavvy.ai observes that equity compensation, including Restricted Stock Units (RSUs) with multi-year vesting schedules, is a standard practice across industries for executive remuneration, aligning with common corporate governance models seen in companies like Pfizer, Merck, and Eli Lilly.
- The disposal of shares to cover tax liabilities upon RSU vesting is a widely accepted and routine practice for executives, consistent with compensation structures at peer companies such as Elanco Animal Health and IDEXX Laboratories.
Stakeholder Impact
- Minimal impact on shareholders as these are routine compensation events and do not signal a change in company fundamentals or strategy.
- For the reporting executive, these transactions represent the realization of previously granted equity compensation.
Next Steps
- Future vesting dates for outstanding Restricted Stock Units on the first, second, and third anniversaries of their respective grant dates (February 6, 2024; February 8, 2023; February 19, 2025; April 30, 2025).
Key Dates
| Date | Description |
|---|---|
| 2023-02-08 | Grant date for certain Restricted Stock Units, with one-third vesting on the first, second, and third anniversaries. |
| 2024-02-06 | Grant date for certain Restricted Stock Units, with one-third vesting on the first, second, and third anniversaries. |
| 2025-02-19 | Grant date for certain Restricted Stock Units, with one-third vesting on the first, second, and third anniversaries. |
| 2025-04-30 | Grant date for certain Restricted Stock Units, with one-third vesting on the first, second, and third anniversaries. |
| 2025-12-31 | Date as of which common stock equivalents in the Zoetis Inc. Savings Plan (401(k) plan) are reported. |
| 2026-02-06 | Transaction date for acquisition of 43 common shares and disposal of 15 common shares for tax withholding. |
| 2026-02-08 | Transaction date for acquisition of 50 common shares and disposal of 18 common shares for tax withholding. |
| 2026-02-10 | Signature date of the reporting person's attorney-in-fact for the filing. |
Recommendation
holdThe filing details routine insider transactions related to executive compensation and tax obligations, which are not indicative of any fundamental change in the company's prospects or valuation. These transactions are part of a pre-arranged plan and do not provide new information to warrant a change in investment recommendation.
Keywords
Zoetis, ZTS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Executive Compensation, Kevin Esch, Stock Transactions, Equity Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.